Abstract
Introduction: Variants in the intron splicing enhancer (ISE) of intron 3 in the GH1 gene are implicated in the etiology of isolated growth hormone deficiency type 2 (type II IGHD). Methods: Exome sequencing was performed to screen variants that co-segregated with IGHD in an extended family with type II IGHD. The causality of the candidate variant was assessed using bioinformatic tools and previous in vitro studies. Results: Exome sequencing identified a rare intronic variant (NM_000515.5, c.291+34 G>A) in the second XGGG repeat of ISE in intron 3 of GH1, which occurred de novo in the mother with IGHD and was passed onto her two affected children. The variant was previously shown in vitro to cause exon 3 skipping in 50% of the mRNAs and was predicted to create a new binding site for exonic splicing enhancer binding proteins (SR proteins). Conclusion: Our familial case reiterates the importance of intronic variants in the splicing enhancer region as a cause of IGHD. Consideration should be given to sequencing the splicing enhancer region in intron 3 of GH1 for patients who undergo genetic testing for growth hormone deficiency.
Journal Section:
Brief Report
References
1.
Alatzoglou
KS
, Turton
JP
, Kelberman
D
, Clayton
PE
, Mehta
A
, Buchanan
C
, et al. Expanding the spectrum of mutations in GH1 and Ghrhr: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency
. J Clin Endocrinol Metab
. 2009
;94
(9
):3191
–9
. 2.
Alatzoglou
KS
, Dattani
MT
. Genetic causes and treatment of isolated growth hormone deficiency: an update
. Nat Rev Endocrinol
. 2010
;6
(10
):562
–76
. 3.
Alatzoglou
K
, Webb
EA
, Le Tissier
P
, Dattani
MT
. Isolated Growth Hormone Deficiency (GHD) in childhood and adolescence: recent advances
. Endocr Rev
. 2014
;35
(3
):376
–432
. 4.
Mullis
PE
. Genetics of isolated growth hormone deficiency
. J Clin Res Pediatr Endocrinol
. 2010
;2
(2
):52
–62
. 5.
Hayashi
Y
, Kamijo
T
, Yamamoto
M
, Ohmori
S
, Phillips
JA
, Ogawa
M
, et al. A novel mutation at the donor splice site of intron 3 of the GH-I gene in a patient with isolated growth hormone deficiency
. Growth Horm IGF Res
. 1999
;9
(6
):434
–7
. 6.
Mullis
PE
, Robinson
I
, Salemi
S
, Eblé
A
, Besson
A
, Vuissoz
JM
, et al. Isolated autosomal dominant growth hormone deficiency: an evolving pituitary deficit? A multicenter follow-up study Multicenter Study
. J Clin Endocrinol Metab
. 2005
;90
(4
):2089
–96
. 7.
Wang
Z
, Burge
CB
. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code
. RNA
. 2008
;14
(5
):802
–13
. 8.
McCarthy
EM
, Phillips
JA
3rd. Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA
. Hum Mol Genet
. 1998
;7
(9
):1491
–6
. 9.
Cogan
JD
, Phillips
JA
, Schenkman
SS
, Milner
RD
, Sakati
N
. Familial growth hormone deficiency: a model of dominant and recessive mutations affecting a monomeric protein
. J Clin Endocrinol Metab
. 1994
;79
(5
):1261
–5
. 10.
Cogan
JD
, Ramel
B
, Lehto
M
, Phillips
J
, Prince
M
, Blizzard
RM
, et al. A recurring dominant negative mutation causes autosomal dominant growth hormone deficiency: A clinical research center study
. J Clin Endocrinol Metab
. 1995
;80
(12
):3591
–5
. 11.
Cogan
JD
, Prince
MA
, Lekhakula
S
, Bundey
S
, Futrakul
A
, McCarthy
EM
, et al. A novel mechanism of aberrant pre-mrna splicing in humans
. Hum Mol Genet
. 1997
;6
(6
):909
–12
. 12.
Jee
YH
, Sowada
N
, Markello
TC
, Rezvani
I
, Borck
G
, Baron
J
. BRF1 mutations in a family with growth failure, markedly delayed bone age, and central nervous system anomalies
. Clin Genet
. 2017
;91
(5
):739
–47
. 13.
Richards
S
, Aziz
N
, Bale
S
, Bick
D
, Das
S
, Gastier-Foster
J
, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology
. Genet Med
. 2015
;17
(5
):405
–24
. 14.
Karczewski
KJ
, Francioli
LC
, Tiao
G
, Cummings
BB
, Alföldi
J
, Wang
Q
, et al. The mutational constraint spectrum quantified from variation in 141,456 humans
. Nature
. 2020
;581
(7809
):434
–43
. 15.
Cartegni
L
, Wang
J
, Zhu
Z
, Zhang
MQ
, Krainer
AR
. ESEfinder: a web resource to identify exonic splicing enhancers
. Nucleic Acids Res
. 2003
;31
(13
):3568
–71
. 16.
Fairbrother
WG
, Yeh
RF
, Sharp
PA
, Burge
CB
. Predictive identification of exonic splicing enhancers in human genes
. Science
. 2002
;297
(5583
):1007
–13
. 17.
Rentzsch
P
, Witten
D
, Cooper
GM
, Shendure
J
, Kircher
M
. CADD: predicting the deleteriousness of variants throughout the human genome
. Nucleic Acids Res
. 2019
;47
(D1
):D886
–94
. 18.
McCullough
AJ
, Berget
SM
. An intronic splicing enhancer binds U1 snRNPs to enhance splicing and select 5' splice sites
. Mol Cell Biol
. 2000
;20
(24
):9225
–35
. 19.
Binder
G
, Keller
E
, Mix
M
, Massa
GG
, Stokvis-Brantsma
WH
, Wit
JM
, et al. Isolated GH deficiency with dominant inheritance: new mutations, New Insights
. J Clin Endocrinol Metab
. 2001
;86
(8
):3877
–81
. 20.
Wang
DS
, Sato
K
, Demura
H
, Kato
Y
, Maruo
N
, Miyachi
Y
. Osteo-anabolic effects of human growth hormone with 22K- and 20K Daltons on human osteoblast-like cells
. Endocr J
. 1999
;46
(1
):125
–32
. 21.
Miletta
MC
, Lochmatter
D
, Pektovic
V
, Mullis
PE
. Isolated growth hormone deficiency type 2: from gene to therapy
. Endocr Dev
. 2012
;23
:109
–20
. 22.
Takahashi
I
, Takahashi
T
, Komatsu
M
, Sato
T
, Takada
G
. An exonic mutation of the GH-1 gene causing familial isolated growth hormone deficiency type II
. Clin Genet
. 2002
;61
(3
):222
–5
. 23.
Wang
Y
, Ma
M
, Xiao
X
, Wang
Z
. Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules
. Nat Struct Mol Biol
. 2012
;19
(10
):1044
–52
. 24.
Walker
LC
, Hoya
M
, Wiggins
GAR
, Lindy
A
, Vincent
LM
, Parsons
MT
, et al. Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: recommendations from the ClinGen SVI Splicing Subgroup
. Am J Hum Genet
. 2023
;110
(7
):1046
–67
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
